Advertisement

ImmunoGen Inc. and its partner, Swiss drug maker Roche AG, announced that the U.S. Food and Drug Administration has awarded a Priority review to its potential  treatment for certain types of breast cancer, called TDM-1. This means the regulatory agency will make a decision on approval within six months, rather than the customary 10. The FDA has given the companies a February 26, 2013 decision date.

Advertisement
Advertisement